Choosing lipid lowering statin in risk strategy of cardiovascular event prevention
Aim. To investigate low density lipoprotein cholesterol (LDL-CH) lowering effectiveness of atorvastatin (Torvacard; 20 mg/d) in patients with moderate hypercholesterolemia (HCH) after 4 and 12 weeks of treatment, together with standard hypolipidemic diet; to assess (%) target LDL-CH level achievemen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2007-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1144 |
| _version_ | 1797882766316011520 |
|---|---|
| author | A. Ya. Yvleva L. A. Alekseeva N. M. Poluboyarova |
| author_facet | A. Ya. Yvleva L. A. Alekseeva N. M. Poluboyarova |
| author_sort | A. Ya. Yvleva |
| collection | DOAJ |
| description | Aim. To investigate low density lipoprotein cholesterol (LDL-CH) lowering effectiveness of atorvastatin (Torvacard; 20 mg/d) in patients with moderate hypercholesterolemia (HCH) after 4 and 12 weeks of treatment, together with standard hypolipidemic diet; to assess (%) target LDL-CH level achievement (<2,5 mmol/l, or 100 mg/dl) in patients of very high cardiovascular risk (risk category 1), receiving atorvastatin (Torvacard; 20 mg/d) for 12 weeks. Material and methods. The trial included 32 patients (20 men aged 40-68 years, 12 women aged 54-67 years). At baseline, all participants had LDL-CH level >3,4 mmol/l (130 mg/d) despite previous standard hypolipidemic diet for at least 4 weeks. Maximal LDL-CH level was as high as 4,5 mmol/l (175 mg/dl). Results. Tovacard lipid-lowering effect was completely manifested after 4 weeks: total CH level decreased by 32%, and at week 12 by 33%. LDL CH levels reduced by 44% and 46%, respectively. High density lipoprotein CH level increased by 6,3% at week 12. Plasma triglyceride levels decreased by 14% and 24% at weeks 4 and 12, respectively. Conclusion. Tovacard (20 mg/d) demonstrated high lipid lowering effectiveness. Atorvastatin generic, Torvacard, could be included into out-patient clinic medicine lists as an effective statin with optimal cost effectiveness and no need for dose titration. |
| first_indexed | 2024-04-10T03:40:57Z |
| format | Article |
| id | doaj.art-d05d475fee2d4d1a97f431f278c3d0bf |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:40:57Z |
| publishDate | 2007-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-d05d475fee2d4d1a97f431f278c3d0bf2023-03-13T07:23:13Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252007-02-01615460856Choosing lipid lowering statin in risk strategy of cardiovascular event preventionA. Ya. Yvleva0L. A. Alekseeva1N. M. Poluboyarova2Поликлиника №3 Управления делами Президента РФ, МоскваПоликлиника №1 Управления делами Президента РФ, МоскваПоликлиника №1 Управления делами Президента РФ, МоскваAim. To investigate low density lipoprotein cholesterol (LDL-CH) lowering effectiveness of atorvastatin (Torvacard; 20 mg/d) in patients with moderate hypercholesterolemia (HCH) after 4 and 12 weeks of treatment, together with standard hypolipidemic diet; to assess (%) target LDL-CH level achievement (<2,5 mmol/l, or 100 mg/dl) in patients of very high cardiovascular risk (risk category 1), receiving atorvastatin (Torvacard; 20 mg/d) for 12 weeks. Material and methods. The trial included 32 patients (20 men aged 40-68 years, 12 women aged 54-67 years). At baseline, all participants had LDL-CH level >3,4 mmol/l (130 mg/d) despite previous standard hypolipidemic diet for at least 4 weeks. Maximal LDL-CH level was as high as 4,5 mmol/l (175 mg/dl). Results. Tovacard lipid-lowering effect was completely manifested after 4 weeks: total CH level decreased by 32%, and at week 12 by 33%. LDL CH levels reduced by 44% and 46%, respectively. High density lipoprotein CH level increased by 6,3% at week 12. Plasma triglyceride levels decreased by 14% and 24% at weeks 4 and 12, respectively. Conclusion. Tovacard (20 mg/d) demonstrated high lipid lowering effectiveness. Atorvastatin generic, Torvacard, could be included into out-patient clinic medicine lists as an effective statin with optimal cost effectiveness and no need for dose titration.https://cardiovascular.elpub.ru/jour/article/view/1144умеренная гиперлипидемиястатиныаторвастатин (торвакард) |
| spellingShingle | A. Ya. Yvleva L. A. Alekseeva N. M. Poluboyarova Choosing lipid lowering statin in risk strategy of cardiovascular event prevention Кардиоваскулярная терапия и профилактика умеренная гиперлипидемия статины аторвастатин (торвакард) |
| title | Choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| title_full | Choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| title_fullStr | Choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| title_full_unstemmed | Choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| title_short | Choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| title_sort | choosing lipid lowering statin in risk strategy of cardiovascular event prevention |
| topic | умеренная гиперлипидемия статины аторвастатин (торвакард) |
| url | https://cardiovascular.elpub.ru/jour/article/view/1144 |
| work_keys_str_mv | AT ayayvleva choosinglipidloweringstatininriskstrategyofcardiovasculareventprevention AT laalekseeva choosinglipidloweringstatininriskstrategyofcardiovasculareventprevention AT nmpoluboyarova choosinglipidloweringstatininriskstrategyofcardiovasculareventprevention |